Phase II open-label study of sunitinib in patients with advanced breast cancer

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

(2012) Jonas Bergh et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

(2011) Carlos H. Barrios et al.   CANCER

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

(2011) Nicholas J. Robert et al.   Clinical Breast Cancer

Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy

(2011) Nils D. Arvold et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer

(2011) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

(2011) Miguel Martin et al.   LANCET ONCOLOGY

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials

(2010) A. Valachis et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

(2010) Carlos H. Barrios et al.   BREAST CANCER RESEARCH AND TREATMENT

A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).

(2010) W. Gradishar et al.   CANCER RESEARCH

SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).

(2010) J. Baselga et al.   CANCER RESEARCH

Molecular Predictors of Locoregional Recurrence in Breast Cancer: Ready for Prime Time?

(2010) Bruce G. Haffty et al.   JOURNAL OF CLINICAL ONCOLOGY

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

(2010) Eleftherios P. Mamounas et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic Behavior of Breast Cancer Subtypes

(2010) Hagen Kennecke et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer

(2009) Janna Paulsson et al.   AMERICAN JOURNAL OF PATHOLOGY

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

(2009) Giulia Bianchi et al.   ANTI-CANCER DRUGS

5029 Motesanib (AMG 706) in combination with paclitaxel or docetaxel: phase 1b study in patients with locally recurrent, unresectable or metastatic breast cancer

(2009) P. Kaufman et al.   EJC SUPPLEMENTS

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

(2009) S. George et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336

(2008) Alvaro Moreno-Aspitia et al.   JOURNAL OF CLINICAL ONCOLOGY